Webinar now available on demand. A comprehensive look at the evolving requirements for early phase CNS drug and cannabinoid development, with recommendations for regulatory strategy and marketing success.
Neuro Central hosted a free online webinar, ‘Drugs and Driving: Discussing the cognitive effects of drugs on driving performance’, featuring…
Our panelists respond to questions from our recent live panel discussion, ‘Brain banking: progress, challenges and opportunities’.
In this hour-long event, held in collaboration between Neuro Central and The Drake Foundation, our expert panel will discuss various aspects of brain banking and its current challenges.
Assessing how drugs affect the CNS is becoming an increasing concern, particularly for road safety. In January 2015, the FDA issued the Draft Guidance – Evaluating Drug Effects on the Ability to Operate a Motor Vehicle. 2 years later, where are we now?
James Coffman responds to questions from our recent webinar, ‘How chronic stress experienced during early development epigenetically programs adult disease risk’.
Epidemiological studies have shown that chronic stress experienced very early in life—even prenatally—increases the risk of developing inflammatory disease in adulthood, including mental health disorders such as anxiety and depression.
Read the Q&A transcript and responses to the unanswered questions from our webinar on ‘Manipulation of Abuse Deterrent Formulations at the Clinical Pharmacology Unit’.
To explore the intricacies of the manipulation of abuse deterrent formulations (ADFs) in the clinical pharmacology unit (CPU) and its relationship to in vitro studies.